China Cancer Pain Management Market Analysis Report [2022-30] I Insights10

China Cancer Pain Management Market Analysis

$ 3999

China's Cancer Pain Management market is projected to grow from $524.13 Mn in 2022 to $887.17 Mn by 2030, registering a CAGR of 6.8% during the forecast period of 2022 - 2030. The main factors driving the growth would be an increase in cancer incidences, growing healthcare expenditure, and an aging population. The market is segmented by drug type and by disease. Some of the major players include Aoxing Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), Hisamitsu Pharmaceutical, Mundipharma, Pfizer, and Teva Pharmaceuticals.

ID: IN10CNHS002 CATEGORY: Healthcare Services GEOGRAPHY: China AUTHOR: Neha Davda

Buy Now

China Cancer Pain Management Market Executive Summary

China's Cancer Pain Management market is projected to grow from $524.13 Mn in 2022 to $887.17 Mn by 2030, registering a CAGR of 6.8% during the forecast period of 2022 - 2030. China's health spending increased from 5.17% of GDP in 2018 to 5.35% in 2019. The cost of healthcare as a proportion of GDP is still lower in developing nations, where it is typically around 10%.

Cancer pain can be caused by the disease itself or by treatments like chemotherapy and surgery. The type, location, and degree of pain experienced have an impact on the choice and use of medications. Pain from cancer is managed with a variety of drugs. For instance, while treating mild to moderate cancer pain, it is recommended to use powerful opioids rather than non-opioids like acetaminophen and NSAIDs. The Asia-Pacific cancer pain management market is one of the rapidly growing markets worldwide.

china cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The China cancer pain management market is expected to be driven by factors such as an increase in cancer incidences and an aging population. The market for cancer pain management products is predicted to grow as a result of the high growth in healthcare spending in China over the past few years.

Market Restraints

Access to cancer pain management products can be difficult in some parts of China, particularly in rural communities with few infrastructure and healthcare facilities. Additionally, the adverse consequences of utilizing drugs to treat cancer pain, such as drug tolerance, drug dependence, urinary retention, difficulty sleeping, cognitive impairment, and others, are likely to restrain the expansion of the cancer pain market.

Competitive Landscape

Key Players

Aoxing Pharmaceutical (CHN)
Jiangsu Hengrui Medicine (CHN)
Hisamitsu Pharmaceutical
Mundipharma
Pfizer
Teva Pharmaceuticals

Notable Recent Deals

January 2020: Mundipharma and Samsung Bioepis have announced a partnership to market Samsung Bioepis' inaugural batch of biosimilar candidates in Taiwan and Hong Kong. The deal covers Samsung Bioepis' biosimilar prospects for cancer and immunology, including SB3 (trastuzumab), SB4 (etanercept), SB5 (adalimumab), and SB8 (bevacizumab).

Healthcare Policies and Regulatory Landscape

The National Health Commission and the China Food and Drug Administration (CFDA) are primarily in charge of regulating the healthcare environment and the pain treatment sector in China. The CFDA has a stringent approval procedure for new medications, including pain relievers, which can restrict the release of cutting-edge and novel pharmaceuticals on the market. Additionally, the government has policies in place to manage the use of opioids and stop the abuse.

Reimbursement Scenario

Depending on the type of treatment and the patient's insurance coverage, the reimbursement scenario for the Chinese market for pain management may change. Through its public insurance program, the New Rural Cooperative Medical Scheme (NCMS), which covers medical costs for residents in rural regions, the government typically offers some reimbursement for medical expenses. However, the NCMS only pays a small percentage of the cost of pain management procedures, thus many patients are still required to foot a sizable portion of the cost.

In addition to the NCMS, China also offers private insurance choices that can offer more thorough coverage for pain management therapies. However, not all patients have access to private insurance, and many do not have these choices.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.